All pirces will goes up-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

xremy
2022-01-12

All pirces will goes up

Hutchmed Gets Breakthrough Therapy Designation for Thrombocytopenia Treatment in China

Hutchmed (China) Ltd. said the Center for Drug Evaluation of China's National Medical Products Admin

Hutchmed Gets Breakthrough Therapy Designation for Thrombocytopenia Treatment in China

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":9002639506,"tweetId":"9002639506","gmtCreate":1641989464808,"gmtModify":1676533669221,"author":{"id":4091425725265930,"idStr":"4091425725265930","authorId":4091425725265930,"authorIdStr":"4091425725265930","name":"xremy","avatar":"https://static.tigerbbs.com/eed128399f7a5afff5ef683e5991f030","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":43,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>All pirces will goes up&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>All pirces will goes up&nbsp;</p></body></html>","text":"All pirces will goes up","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/9002639506","repostId":1105283805,"repostType":4,"repost":{"id":"1105283805","kind":"news","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1641987727,"share":"https://www.laohu8.com/m/news/1105283805?lang=&edition=full","pubTime":"2022-01-12 19:42","market":"us","language":"en","title":"Hutchmed Gets Breakthrough Therapy Designation for Thrombocytopenia Treatment in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1105283805","media":"Dow Jones","summary":"Hutchmed (China) Ltd. said the Center for Drug Evaluation of China's National Medical Products Admin","content":"<html><head></head><body><p>Hutchmed (China) Ltd. said the Center for Drug Evaluation of China&#39;s National Medical Products Administration has granted breakthrough therapy designation to HMPL-523, a spleen tyrosine kinase inhibitor, for the treatment of chronic adult primary immune thrombocytopenia patients who have received at least one prior therapy.</p><p>Hutchmed said that with breakthrough designation, it believes it can accelerate the development of HMPL-523 in China.</p><p>The company said the designation is supported by results from a Phase Ib study of HMPL-523. The data also supported the initiation of a Phase III trial, ESLIM-01, in China of HMPL-523 in adult patients with ITP in October. About 180 patients are expected to be enrolled.</p><p>The company said the NMPA grants breakthrough therapy designation to new drugs that treat life-threatening diseases or serious conditions for which there are no effective treatment options, and where clinical evidence demonstrates significant advantages over existing therapies. Drug candidates with breakthrough therapy designation may be considered for conditional approval and priority review when submitting a New Drug Application.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hutchmed Gets Breakthrough Therapy Designation for Thrombocytopenia Treatment in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHutchmed Gets Breakthrough Therapy Designation for Thrombocytopenia Treatment in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-01-12 19:42</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Hutchmed (China) Ltd. said the Center for Drug Evaluation of China&#39;s National Medical Products Administration has granted breakthrough therapy designation to HMPL-523, a spleen tyrosine kinase inhibitor, for the treatment of chronic adult primary immune thrombocytopenia patients who have received at least one prior therapy.</p><p>Hutchmed said that with breakthrough designation, it believes it can accelerate the development of HMPL-523 in China.</p><p>The company said the designation is supported by results from a Phase Ib study of HMPL-523. The data also supported the initiation of a Phase III trial, ESLIM-01, in China of HMPL-523 in adult patients with ITP in October. About 180 patients are expected to be enrolled.</p><p>The company said the NMPA grants breakthrough therapy designation to new drugs that treat life-threatening diseases or serious conditions for which there are no effective treatment options, and where clinical evidence demonstrates significant advantages over existing therapies. Drug candidates with breakthrough therapy designation may be considered for conditional approval and priority review when submitting a New Drug Application.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HCM":"和黄医药","00013":"和黄医药"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105283805","content_text":"Hutchmed (China) Ltd. said the Center for Drug Evaluation of China's National Medical Products Administration has granted breakthrough therapy designation to HMPL-523, a spleen tyrosine kinase inhibitor, for the treatment of chronic adult primary immune thrombocytopenia patients who have received at least one prior therapy.Hutchmed said that with breakthrough designation, it believes it can accelerate the development of HMPL-523 in China.The company said the designation is supported by results from a Phase Ib study of HMPL-523. The data also supported the initiation of a Phase III trial, ESLIM-01, in China of HMPL-523 in adult patients with ITP in October. About 180 patients are expected to be enrolled.The company said the NMPA grants breakthrough therapy designation to new drugs that treat life-threatening diseases or serious conditions for which there are no effective treatment options, and where clinical evidence demonstrates significant advantages over existing therapies. Drug candidates with breakthrough therapy designation may be considered for conditional approval and priority review when submitting a New Drug Application.","news_type":1},"isVote":1,"tweetType":1,"viewCount":461,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":19,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}